Background The optimal initial therapy of follicular lymphoma (FL) remains unclear. The
aims of this study were to compare primary treatment strategies and assess the impact of …

Background Few studies have evaluated real-world treatment patterns and survival in
follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed …

Standard of care for patients with symptomatic, advanced‐stage follicular lymphoma (FL) is
rituximab‐containing chemoimmunotherapy followed by rituximab maintenance. This …

Introduction In their lifetime, patients with follicular lymphoma frequently require multiple
treatments, which have improved their survival over the past few decades. The expected …

Opinion Statement The optimal initial treatment of follicular lymphoma (FL) is not known, and
initial management of patients varies considerably between providers and institutions. The …

Follicular lymphoma (FL) is the second most common lymphoma in the United States and is
characterized by a variable clinical course, disease heterogeneity, and a relapse-and …

Abstract Abstract 1803 Introduction: The recently reported PRIMA trial was the first to
evaluate the benefit of rituximab maintenance (R-maintenance) following first-line …

Purpose In low–tumor burden follicular lymphoma (FL), maintenance rituximab (MR) has
been shown to improve progression-free survival when compared with observation. It is not …

BACKGROUND. It is unclear whether new treatment modalities have improved the survival
of follicular lymphoma patients. Some data show that there has been no improvement in …

Background The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL)
demonstrated higher overall (ORR) and complete response (CR) rates and prolonged …